Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506

被引:29
作者
Fukunaga, J
Yamaai, T
Yamachika, E
Ishiwari, Y
Tsujigiwa, H
Sawaki, K
Lee, YJ
Ueno, T
Kirino, S
Mizukawa, N
Takagi, S
Nagai, N
Sugahara, T
机构
[1] Okayama Univ, Grad Sch Med & Dent, Dept Oral & Maxillofacial Reconstruct Surg, Okayama 7008525, Japan
[2] Okayama Univ, Grad Sch Med & Dent, Dept Oral Funct & Anat, Okayama 7008525, Japan
[3] Okayama Univ, Grad Sch Med & Dent, Dept Oral Pathol & Med, Okayama 7008525, Japan
关键词
ODF; OCIF; osteoporosis; immunosuppressant; FK506; osteoblast;
D O I
10.1016/j.bone.2003.05.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immunosuppressant drugs are currently required by transplant recipients for the remainder of their lives, despite the many adverse effects associated with these therapies. Acute osteoporosis is one such effect, and a reproducible osteoporosis model has been established through the administration of the immunosuppressant drug FK506 in rats. The cause of this osteoporosis has been shown to be abnormal osteoclast proliferation.. altering the process of bone remodeling. However, the reasons why FK506 induces osteoclast proliferation and whether this process is mediated by cytokine changes or an increase in bone resorption factors have been unclear, An investigation was therefore conducted focusing on the recent discoveries of osteoclast differentiation factor (ODF) and osteoclastogenesis inhibitory factor (OCIF). These factors led to elucidation of the osteoclast differentiation-maturation mechanism. An osteoporosis model was produced in rats utilizing intramuscular FK506 injection (1 mg/kg) for 28 consecutive days. Trabecular bone resorption was observed inferior to enchondral ossification in the FK506 group, and tartrate resistant acid phosphatase (TRAP) staining revealed a clear increase in osteoclasts at the site of enchondral ossification, relative to the control group. Real-time PCR and in situ hybridization (ISH) demonstrated minimal differences in OCIF expression between control and the treatment groups. However, Real-time PCR revealed clearly increased ODF expression in the treatment group. ODF expression was also shown to be increased in the treatment group using ISH. This was histologically consistent with a region of osteoclast proliferation inferior to enchondral ossification. The results of this study support the hypothesis that FK506-mediated osteoporosis occurs by action of the drug on osteoclasts, promoting expression of ODF messenger ribonucleic acid (mRNA) and thus prompting osteoclast differentiation and maturation. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:425 / 431
页数:7
相关论文
共 29 条
[21]   MOLECULAR MECHANISMS MEDIATING PROLIFERATION DIFFERENTIATION INTERRELATIONSHIPS DURING PROGRESSIVE DEVELOPMENT OF THE OSTEOBLAST PHENOTYPE [J].
STEIN, GS ;
LIAN, JB .
ENDOCRINE REVIEWS, 1993, 14 (04) :424-442
[22]   MODULATION OF OSTEOCLAST DIFFERENTIATION [J].
SUDA, T ;
TAKAHASHI, N ;
MARTIN, TJ .
ENDOCRINE REVIEWS, 1992, 13 (01) :66-80
[23]   Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection [J].
Teng, YTA ;
Nguyen, H ;
Gao, XJ ;
Kong, YY ;
Gorczynski, RM ;
Singh, B ;
Ellen, RP ;
Penninger, JM .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (06) :R59-R67
[24]   Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis [J].
Tsuda, E ;
Goto, M ;
Mochizuki, S ;
Yano, K ;
Kobayashi, F ;
Morinaga, T ;
Higashio, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 234 (01) :137-142
[25]   Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor [J].
Udagawa, N ;
Takahashi, N ;
Jimi, E ;
Matsuzaki, K ;
Tsurukai, T ;
Itoh, K ;
Nakagawa, N ;
Yasuda, H ;
Goto, M ;
Tsuda, E ;
Higashio, K ;
Gillespie, MT ;
Martin, TJ ;
Suda, T .
BONE, 1999, 25 (05) :517-523
[26]   TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells [J].
Wong, BR ;
Rho, JR ;
Arron, J ;
Robinson, E ;
Orlinick, J ;
Chao, M ;
Kalachikov, S ;
Cayani, E ;
Bartlett, FS ;
Frankel, WN ;
Lee, SY ;
Choi, YW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :25190-25194
[27]   Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):: A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro [J].
Yasuda, H ;
Shima, N ;
Nakagawa, N ;
Mochizuki, SI ;
Yano, K ;
Fujise, N ;
Sato, Y ;
Goto, M ;
Yamaguchi, K ;
Kuriyama, M ;
Kanno, T ;
Murakami, A ;
Tsuda, E ;
Morinaga, T ;
Higashio, K .
ENDOCRINOLOGY, 1998, 139 (03) :1329-1337
[28]   A novel molecular mechanism modulating osteoclast differentiation and function [J].
Yasuda, H ;
Shima, N ;
Nakagawa, N ;
Yamaguchi, K ;
Kinosaki, M ;
Goto, M ;
Mochizuki, SI ;
Tsuda, E ;
Morinaga, T ;
Udagawa, N ;
Takahashi, N ;
Suda, T ;
Higashio, K .
BONE, 1999, 25 (01) :109-113
[29]   Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL [J].
Yasuda, H ;
Shima, N ;
Nakagawa, N ;
Yamaguchi, K ;
Kinosaki, M ;
Mochizuki, S ;
Tomoyasu, A ;
Yano, K ;
Goto, M ;
Murakami, A ;
Tsuda, E ;
Morinaga, T ;
Higashio, K ;
Udagawa, N ;
Takahashi, N ;
Suda, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3597-3602